Osmotic Stress Changes the Expression and Subcellular Localization of the Batten Disease Protein CLN3

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Getty, Amanda ^a   Kovács, Attila D ^a   Lengyel Nelson, Tímea ^a   Cardillo, Andrew ^a   Hof, Caitlin ^a   Chan, Chun Hung ^a   Pearce, David A ^a,b  

^a SANFORD RESEARCH   (United States)

^b UNIVERSITY OF SOUTH DAKOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MEMBRANE PROTEIN; MESSENGER RNA; PROTEIN CLN3; UBIQUITIN C; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CAVEOLA; CELL NUCLEUS; CELLULAR DISTRIBUTION; CONTROLLED STUDY; ENDOSOME; GOLGI COMPLEX; HYPEROSMOLARITY; LYSOSOME; NEURONAL CEROID LIPOFUSCINOSIS; NONHUMAN; OSMOTIC STRESS; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ADAPTATION, PHYSIOLOGICAL; ANIMALS; CELL LINE; CLONING, MOLECULAR; CRICETINAE; ENDOSOMES; GENE EXPRESSION; GLYCOSYLATION; GOLGI APPARATUS; HUMANS; MEMBRANE GLYCOPROTEINS; MOLECULAR CHAPERONES; OSMOTIC PRESSURE; PROMOTER REGIONS, GENETIC; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEIN TRANSPORT; RNA, MESSENGER; STRESS, PHYSIOLOGICAL; TRANSCRIPTIONAL ACTIVATION; UBIQUITIN C; UP-REGULATION;

CRICETINAE;

EID: 84879275667     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0066203     Document Type: Article

References (57)

1. Williams RE, Mole SE, (2012) New nomenclature and classification scheme for the neuronal ceroid lipofuscinoses. Neurology 79: 183-191.
2. Isolation of a novel gene underlying Batten disease, CLN3. The International Batten Disease Consortium. Cell 82: 949-957.
3. Kwon JM, Adams H, Rothberg PG, Augustine EF, Marshall FJ, et al. (2011) Quantifying physical decline in juvenile neuronal ceroid lipofuscinosis (Batten disease). Neurology 77: 1801-1807.
4. Cooper JD, (2008) Moving towards therapies for juvenile Batten disease? Exp Neurol 211: 329-331.
5. Phillips SN, Benedict JW, Weimer JM, Pearce DA, (2005) CLN3, the protein associated with batten disease: structure, function and localization. J Neurosci Res 79: 573-583.
6. Ezaki J, Takeda-Ezaki M, Koike M, Ohsawa Y, Taka H, et al. (2003) Characterization of Cln3p, the gene product responsible for juvenile neuronal ceroid lipofuscinosis, as a lysosomal integral membrane glycoprotein. J Neurochem 87: 1296-1308.
7. Kyttala A, Ihrke G, Vesa J, Schell MJ, Luzio JP, (2004) Two motifs target Batten disease protein CLN3 to lysosomes in transfected nonneuronal and neuronal cells. Mol Biol Cell 15: 1313-1323.
8. Storch S, Pohl S, Quitsch A, Falley K, Braulke T, (2007) C-Terminal Prenylation of the CLN3 Membrane Glycoprotein Is Required for Efficient Endosomal Sorting to Lysosomes. Traffic 8: 431-444.
9. Kaczmarski W, Wisniewski KE, Golabek A, Kaczmarski A, Kida E, et al. (1999) Studies of membrane association of CLN3 protein. Mol Genet Metab 66: 261-264.
10. Pullarkat RK, Morris GN, (1997) Farnesylation of Batten disease CLN3 protein. Neuropediatrics 28: 42-44.
11. Kida E, Kaczmarski W, Golabek AA, Kaczmarski A, Michalewski M, et al. (1999) Analysis of intracellular distribution and trafficking of the CLN3 protein in fusion with the green fluorescent protein in vitro. Mol Genet Metab 66: 265-271.
12. Kyttala A, Yliannala K, Schu P, Jalanko A, Luzio JP, (2005) AP-1 and AP-3 facilitate lysosomal targeting of Batten disease protein CLN3 via its dileucine motif. J Biol Chem 280: 10277-10283.
13. Storch S, Pohl S, Braulke T, (2004) A dileucine motif and a cluster of acidic amino acids in the second cytoplasmic domain of the batten disease-related CLN3 protein are required for efficient lysosomal targeting. J Biol Chem 279: 53625-53634.
14. Jarvela I, Lehtovirta M, Tikkanen R, Kyttala A, Jalanko A, (1999) Defective intracellular transport of CLN3 is the molecular basis of Batten disease (JNCL). Hum Mol Genet 8: 1091-1098.
15. Michalewski MP, Kaczmarski W, Golabek AA, Kida E, Kaczmarski A, et al. (1998) Evidence for phosphorylation of CLN3 protein associated with Batten disease. Biochem Biophys Res Commun 253: 458-462.
16. Michalewski MP, Kaczmarski W, Golabek AA, Kida E, Kaczmarski A, et al. (1999) Posttranslational modification of CLN3 protein and its possible functional implication. Mol Genet Metab 66: 272-276.
17. Mao Q, Xia H, Davidson BL, (2003) Intracellular trafficking of CLN3, the protein underlying the childhood neurodegenerative disease, Batten disease. FEBS Lett 555: 351-357.
18. Golabek AA, Kaczmarski W, Kida E, Kaczmarski A, Michalewski MP, et al. (1999) Expression studies of CLN3 protein (battenin) in fusion with the green fluorescent protein in mammalian cells in vitro. Mol Genet Metab 66: 277-282.
19. Haskell RE, Carr CJ, Pearce DA, Bennett MJ, Davidson BL, (2000) Batten disease: evaluation of CLN3 mutations on protein localization and function. Hum Mol Genet 9: 735-744.
20. Jarvela I, Sainio M, Rantamaki T, Olkkonen VM, Carpen O, et al. (1998) Biosynthesis and intracellular targeting of the CLN3 protein defective in Batten disease. Hum Mol Genet 7: 85-90.
21. Persaud-Sawin DA, McNamara JO, 2nd, Rylova S, Vandongen A, Boustany RM (2004) A galactosylceramide binding domain is involved in trafficking of CLN3 from Golgi to rafts via recycling endosomes. Pediatr Res 56: 449-463.
22. Kremmidiotis G, Lensink IL, Bilton RL, Woollatt E, Chataway TK, et al. (1999) The Batten disease gene product (CLN3p) is a Golgi integral membrane protein. Hum Mol Genet 8: 523-531.
23. Margraf LR, Boriack RL, Routheut AA, Cuppen I, Alhilali L, et al. (1999) Tissue expression and subcellular localization of CLN3, the Batten disease protein. Mol Genet Metab 66: 283-289.
24. Luiro K, Kopra O, Lehtovirta M, Jalanko A, (2001) CLN3 protein is targeted to neuronal synapses but excluded from synaptic vesicles: new clues to Batten disease. Hum Mol Genet 10: 2123-2131.
25. Qin JY, Zhang L, Clift KL, Hulur I, Xiang AP, et al. (2010) Systematic comparison of constitutive promoters and the doxycycline-inducible promoter. PLoS One 5: e10611.
26. Stein CS, Yancey PH, Martins I, Sigmund RD, Stokes JB, et al. (2010) Osmoregulation of Ceroid Neuronal Lipofuscinosis Type 3 (CLN3) in the Renal Medulla. Am J Physiol Cell Physiol.
27. Brenner BM, Rector FC (2008) Brenner & Rector's the kidney. Philadelphia: Saunders Elsevier.
28. Uusi-Rauva K, Luiro K, Tanhuanpaa K, Kopra O, Martin-Vasallo P, et al. (2008) Novel interactions of CLN3 protein link Batten disease to dysregulation of fodrin-Na+, K+ ATPase complex. Exp Cell Res 314: 2895-2905.
29. Kama R, Kanneganti V, Ungermann C, Gerst JE, (2011) The yeast Batten disease orthologue Btn1 controls endosome-Golgi retrograde transport via SNARE assembly. J Cell Biol 195: 203-215.
30. Wolfe DM, Padilla-Lopez S, Vitiello SP, Pearce DA, (2011) pH-dependent localization of Btn1p in the yeast model for Batten disease. Dis Model Mech 4: 120-125.
31. Codlin S, Mole SE, (2009) S. pombe btn1, the orthologue of the Batten disease gene CLN3, is required for vacuole protein sorting of Cpy1p and Golgi exit of Vps10p. J Cell Sci 122: 1163-1173.
32. Agca C, Fritz JJ, Walker LC, Levey AI, Chan AW, et al. (2008) Development of transgenic rats producing human beta-amyloid precursor protein as a model for Alzheimer's disease: transgene and endogenous APP genes are regulated tissue-specifically. BMC Neurosci 9: 28.
33. Getty AL, Pearce DA (2010) Interactions of the proteins of neuronal ceroid lipofuscinosis: clues to function. Cell Mol Life Sci.
34. Ko BC, Ruepp B, Bohren KM, Gabbay KH, Chung SS, (1997) Identification and characterization of multiple osmotic response sequences in the human aldose reductase gene. J Biol Chem 272: 16431-16437.
35. Kast C, Wang M, Whiteway M, (2003) The ERK/MAPK pathway regulates the activity of the human tissue factor pathway inhibitor-2 promoter. J Biol Chem 278: 6787-6794.
36. Arakawa Y, Kajino K, Kano S, Tobita H, Hayashi J, et al. (2004) Transcription of dbpA, a Y box binding protein, is positively regulated by E2F1: implications in hepatocarcinogenesis. Biochem Biophys Res Commun 322: 297-302.
37. Uchiumi F, Sakakibara G, Sato J, Tanuma S, (2008) Characterization of the promoter region of the human PARG gene and its response to PU.1 during differentiation of HL-60 cells. Genes Cells 13: 1229-1247.
38. Lin GG, Kozaki T, Scott JG, (2011) Hormone receptor-like in 96 and Broad-Complex modulate phenobarbital induced transcription of cytochrome P450 CYP6D1 in Drosophila S2 cells. Insect Mol Biol 20: 87-95.
39. Wu YL, Peng XE, Wang D, Chen WN, Lin X, (2012) Human liver fatty acid binding protein (hFABP1) gene is regulated by liver-enriched transcription factors HNF3beta and C/EBPalpha. Biochimie 94: 384-392.
40. Heinemeyer T, Wingender E, Reuter I, Hermjakob H, Kel AE, et al. (1998) Databases on transcriptional regulation: TRANSFAC, TRRD and COMPEL. Nucleic Acids Res 26: 362-367.
41. Shieh BH, Sparkes RS, Gaynor RB, Lusis AJ, (1993) Localization of the gene-encoding upstream stimulatory factor (USF) to human chromosome 1q22-q23. Genomics 16: 266-268.
42. Wechsler J, Greene M, McDevitt MA, Anastasi J, Karp JE, et al. (2002) Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome. Nat Genet 32: 148-152.
43. Yokoyama C, Wang X, Briggs MR, Admon A, Wu J, et al. (1993) SREBP-1, a basic-helix-loop-helix-leucine zipper protein that controls transcription of the low density lipoprotein receptor gene. Cell 75: 187-197.
44. Rabindran SK, Giorgi G, Clos J, Wu C, (1991) Molecular cloning and expression of a human heat shock factor, HSF1. Proc Natl Acad Sci U S A 88: 6906-6910.
45. Schuetz TJ, Gallo GJ, Sheldon L, Tempst P, Kingston RE, (1991) Isolation of a cDNA for HSF2: evidence for two heat shock factor genes in humans. Proc Natl Acad Sci U S A 88: 6911-6915.
46. Lo Coco F, Pisegna S, Diverio D, (1997) The AML1 gene: a transcription factor involved in the pathogenesis of myeloid and lymphoid leukemias. Haematologica 82: 364-370.
47. Karin M, Liu Z, Zandi E, (1997) AP-1 function and regulation. Curr Opin Cell Biol 9: 240-246.
48. Caruccio L, Bae S, Liu AY, Chen KY, (1997) The heat-shock transcription factor HSF1 is rapidly activated by either hyper- or hypo-osmotic stress in mammalian cells. Biochem J 327 (Pt 2): 341-347.
49. Christoph K, Beck FX, Neuhofer W, (2007) Osmoadaptation of Mammalian cells- an orchestrated network of protective genes. Curr Genomics 8: 209-218.
50. Khan AH, Lin A, Smith DJ, (2012) Discovery and characterization of human exonic transcriptional regulatory elements. PLoS One 7: e46098.
51. Munishkina LA, Ahmad A, Fink AL, Uversky VN, (2008) Guiding protein aggregation with macromolecular crowding. Biochemistry 47: 8993-9006.
52. Ellis RJ, Minton AP, (2006) Protein aggregation in crowded environments. Biol Chem 387: 485-497.
53. Burg MB, Ferraris JD, Dmitrieva NI, (2007) Cellular response to hyperosmotic stresses. Physiol Rev 87: 1441-1474.
54. Pedersen SF, Hoffmann EK, (2002) Possible interrelationship between changes in F-actin and myosin II, protein phosphorylation, and cell volume regulation in Ehrlich ascites tumor cells. Exp Cell Res 277: 57-73.
55. Getty AL, Benedict JW, Pearce DA, (2011) A novel interaction of CLN3 with nonmuscle myosin-IIB and defects in cell motility of Cln3(-/-) cells. Exp Cell Res 317: 51-69.
56. Mao L, Hartl D, Nolden T, Koppelstatter A, Klose J, et al. (2008) Pronounced alterations of cellular metabolism and structure due to hyper- or hypo-osmosis. J Proteome Res 7: 3968-3983.
57. Mayran N, Parton RG, Gruenberg J, (2003) Annexin II regulates multivesicular endosome biogenesis in the degradation pathway of animal cells. Embo J 22: 3242-3253.